Press Releases

Manuscript Describes How TLC’s Inhalable Liposomal Hydroxychloroquine May Provide Clinical Benefit and Serve as Potential Treatment for COVID-19


Achieving 30x exposure in lungs at significantly lower dose while reducing systemic and cardiac toxicities

TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that a pre-print version of a manuscript on TLC’s strategy to treat COVID-19 disease with targeted delivery of inhalable liposomal hydroxychloroquine has been made publicly available.

Hydroxychloroquine (HCQ) is an anti-malarial and anti-inflammatory drug that has been shown to inhibit SARS-CoV-2 infection in vitro and tested in clinical studies. However, recent clinical trials studying orally ingested HCQ have shown inconclusive results due to the extremely high doses required to achieve effective antiviral levels.  The manuscript describes a nonclinical pharmacokinetics study in which, comparing equivalent doses of inhalable liposomal HCQ to intravenous (to represent oral) unformulated HCQ, inhalable liposomal HCQ achieved increased exposure (~30-fold) and half-life (~2.5-fold) in the lungs while also achieving lower blood and heart exposure. Moreover, the study results suggest a sustained release, liposomal formulation of HCQ might provide preferentially higher concentrations in the lung than an aerosolized, non-liposomal HCQ formulation, which is retained in the lung only transiently and distributed rapidly from lung to systemic circulation. An inhalable liposomal formulation of HCQ would require significantly lower doses - a tiny fraction of the oral dose - to achieve sufficient and locally sustained drug exposure in the lungs, reducing the systemic and cardiac toxicities commonly seen with high doses of oral HCQ.

“A global pandemic requires a global effort. In these unprecedented times, we should all put the wellbeing of the people first and do what we can to help,” said George Yeh, President of TLC. “TLC has long been aware of the advantages of inhalable liposomal formulations in the treatment of infectious and inflammatory lung diseases, and we are grateful to have started the development of a potential treatment for COVID-19 before it became a pandemic. We hope that the promising results seen in our animal studies will draw attention from organizations around the world and result in a global and expedited development of inhalable liposome HCQ to deliver a potential treatment that the world needs as quickly as possible.”

The manuscript, entitled “A Strategy to Treat COVID-19 Disease with Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Non-clinical Pharmacokinetic Study”, has been submitted for publication and is currently under peer review. The pre-print full manuscript can be accessed at the following link: